This review presents basic data on the hypothalamo-hypophyseal system (HHS) and its main components; the role of age (with the focus on aging) is discussed as a factor linked with changes in the state of the HHS and mediating its involvement in “preparative” predisposition to various major chronic noncommunicable diseases in humans (in particular, such neoplasms as cancer of the breast, endometrium, and prostate; ischemic heart disease as the leading cardiovascular pathology; type 2 diabetes mellitus) with the involvement of this major hormonal-metabolic system via obesity, insulin resistance, and decreased glucose tolerance, as well as the interaction of insulin, insulin-like growth factor 1, and their receptors and effects on the reproductive and hypothalamo-hypophyseal-adrenal system. Data are presented on links between HHS subsystems in stress conditions, impairments to physiological rhythms, and in response to the gender factor. This review presents information on possible measures to prevent the main noncommunicable diseases based on consideration of the role of the HHS and the outcomes of impairments to its functioning. The review also addresses the fact that along with the widely accepted similarity in the hormonal-metabolic factors creating a platform for the development of the main noncommunicable diseases, there are examples of nonsimilarity, a point which requires further research.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
A. O. Shpakov, Gonadotropins: from Theory to Clinical Practice, Politech-Press, St. Petersburg (2018).
L. Gooren, “Androgens and estrogens in their negative feedback action in the hypothalamo-pituitary-testis axis: site of action and evidence of their interaction,” J. Steroid. Biochem., 33, 757–761 (1989).
V. M. Dilman and V. N. Anisimov, “Hypothalamic mechanisms of ageing and of specific age pathology. I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system,” Exp. Gerontol., 14, No. 4, 161–174 (1979).
J. Miyamoto, T. Matsumoto, H. Shiina, et al., “The pituitary function of androgen receptor constitutes a glucocorticoid production circuit,” Mol. Cell. Biol., 27, 4807–4814 (2007).
S. Proietto, L. Yankelevich, F. M. Villarreal, et al., “American plains vizcacha, Lagostomus maximus, Rodentia, Caviomorpha,” Gen. Comp. Endocrinol., 273, 40–51 (2019).
N. Rimon-Dahari, L. Yerushalmi-Heinemann, L. Alyagor, and N. Dekel, “Ovarian folliculogenesis,” Results Probl. Cell. Differ., 58, 167–190 (2016).
A. O. Shpakov and K. V. Derkach, “New advances in studies of endogenous regulators of gonadotropin synthesis and secretion,” Ros. Fiziol. Zh., 12, 1409–1427 (2018).
Y. Xu, J. Xie, L. Wan, et al., “Follistatin-like 3, an activin A binding protein, is involved in early pregnancy loss,” Biomed. Pharmacother., 121, 109577 (2020).
A. O. Shpakov, “Visfatin and its role in the regulation of the reproductive system,” Translyats. Med., 2, 225–236 (2019).
H. Darabi, A. Ostovar, A. Raeisi, et al., “The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study,” Endocr. Res., 42, No. 3, 191–197 (2017).
M. Tyczewska, P. Milecka, M. Szyszka, et al., “Expression profile of Galp, alarin and their receptors in rat adrenal gland,” Adv. Clin. Exp. Med., 28, No. 6, 737–746 (2019).
A. Makrigiannakis, T. Vrekoussis, E. Zoumakis, et al., “CRH receptors in human reproduction,” Curr. Mol. Pharmacol., 11, No. 1, 81– 87 (2018).
J. Robert, R. J. Handa, and M. J. Weiser, “Gonadal steroid hormones and the hypothalamo-pituitary-adrenal axis,” Front. Neuroendocrinol., 35, No. 2, 197–220 (2014).
S. N. Kalantaridou, A. Makrigiannakis, E. Zoumakis, and G. P. Chrousos, “Reproductive functions of corticotropin-releasing hormone; research and potential clinical utility of antalarmins CRH receptor type 1 antagonists,” Am. J. Reprod. Immunol., 51, No. 4, 269–74 (2004).
T. M. Ortiga-Carvalho, M. I. Chiamolera, C. C. Pazos-Moura, and F. E. Wondisford, “Hypothalamus-pituitary-thyroid axis,” Compr. Physiol., 6, No. 3, 1387–4283 (2016).
R. Hoermann, J. E. M. Midgley, R. Larisch, and J. W. Dietrich, “The role of functional thyroid capacity in pituitary thyroid feedback regulation,” Eur. J. Clin. Invest., 48, No. 10, e13003 (2018).
V. Di Paolo, C. Mangialardo, C. Zacà, et al., “Thyroid hormones T3 and T4 regulate human luteinized granulosa cells, counteracting apoptosis and promoting cell survival,” J. Endocrinol. Invest., 43m, No. 6, 821–831 (2020), https://doi.org/10.1007/s40618-019-01169-5.
A. H. Van der Spek, O. V. Surovtseva, K. K. Jim, et al., “Regulation of intracellular triiodothyronine is essential for optimal macrophage function,” Endocrinology, 159, No. 5, 2241–2252 (2018).
C. Fekete and R. M. Lechan, “Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions,” Endocrine Rev., 30, No. 2, 159–194 (2014).
M. Ghamari-Langroudi, D. Srisai, and R. D. Cone, “Multinodal regulation of the arcuate/paraventricular nucleus circuit by leptin,” Proc. Natl. Acad. Sci. USA, 108, 355–360 (2011).
A. C. Panveloski-Costa, C. Serrano-Nascimento, P. Bargi-Souza, et al., “Benefi cial effects of thyroid hormone on adipose inflammation and insulin sensitivity of obese Wistar rats,” Physiol. Rep., 6, No. 3, e13550 (2018).
H. E. Bergan-Roller and M. A. Sheridan, “The growth hormone signaling system: Insights into coordinating the anabolic and catabolic actions of growth hormone,” Gen. Comp. Endocrinol., 258, 119–133 (2018).
H. E. Bergan-Roller, A. T. Ickstadt, J. D. Kittilson, and M. A. Sheridan, “Insulin and insulin-like growth factor-1 modulate the lipolytic action of growth hormone by altering signal pathway linkages,” Gen. Comp. Endocrinol., 248, 40–48 (2017).
H. Qiu, J. K. Yang, and C. Chen, “Influence of insulin on growth hormone secretion, level and growth hormone signalling,” Sheng Li Xue Bao, 69, No. 5, 541–556 (2017).
G. Mazziotti and A. Giustina, “Glucocorticoids and the regulation of growth hormone secretion,” Nat. Rev. Endocrinol., 9, No. 5, 265–276 (2013).
D. M. Huffman, G. Farias Quipildor, K. Mao, et al., “Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of agerelated insulin resistance and IGF-1 decline,” Aging Cell, 1, 181–186 (2016).
V. M. Dil’man, Four Models of Medicine, Meditsina, Leningrad (1987).
E. H. Gan and R. Quinton, “Physiological significance of the rhythmic secretion of hypothalamic and pituitary hormones,” Prog. Brain Res., 181, 111–126 (2010).
B. Gustafson, S. Hedjazifar, S. Gogg, et al., “Insulin resistance and impaired adipogenesis,” Trends Endocrinol. Metab., 4, 193–200 (2015).
B. Gustafson, A. Nerstedt, and U. Smith, “Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells,” Nat. Commun., 10, No. 1, 2757 (2019).
E. M. Ràfols, “Adipose tissue: cell heterogeneity and functional diversity,” Endocrinol. Nutr., 61, No. 2, 100–112 (2014).
A. Cignarelli, V. A. Genchi, S. Perrini, et al., “Insulin and insulin receptors in adipose tissue development,” Int. J. Mol. Sci., 20, No. 3, 759 (2019).
M. G. Oyola and R. J. Handa, “Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes: sex differences in regulation of stress responsivity,” Stress, 20, No. 5, 476–494 (2017).
A. E. Gaffey, C. S. Bergeman, L. A. Clark, and M. M. Wirth, “Aging and the HPA axis: Stress and resilience in older adults,” Neurosci. Biobehav. Rev., 68, 928–945 (2016).
F. Xiong and L. Zhang, “Role of the hypothalamic-pituitary-adrenal axis in developmental programming of health and disease,” Front. Neuroendocrinol., 34, No. 1, 27–46 (2013).
N. C. Vamvakopoulos and G. P. Chrousos, “Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/infl ammatory reaction,” J. Clin. Invest., 92, 1896–1902 (1993).
R. T. Rubin, M. E. Rhodes, S. O’Toole, and R. K. Czambel, “Sexual diergism of hypothalamo-pituitary-adrenal cortical responses to low-dose physotigmine in elderly vs. young women and men,” Neuropsychopharmacology, 26, No. 5, 672–681 (2002).
E. Ferrari and F. Magri, “Role of neuroendocrine pathways in cognitive decline during aging,” Ageing Res. Rev., 7, 225–233 (2008).
E. H. Gan and R. Quinton, “Physiological signifi cance of the rhythmic secretion of hypothalamic and pituitary hormones,” Prog. Brain Res., 181, 111–126 (2010).
J. Ayuk and M. C. Sheppard, “Does acromegaly enhance mortality?” Rev. Endocr. Metab. Disord., 9, 33–39 (2008).
R. A. Miller, J. M. Harper, A. Galecki, and D. T. Burke, “Big mice die young: early life body weight predicts longevity in genetically heterogeneous mice,” Aging Cell, 1, 22–29 (2002).
M. H. Aguiar-Oliveira, F. T. Oliveira, R. M. Pereira, et al., “Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene,” J. Clin. Endocrinol. Metab., 95, 714–21 (2010).
J. O. Jørgensen, M. Krag, N. Jessen, et al., “Growth hormone and glucose homeostasis,” Horm. Res., 62, 51–55 (2004).
M. C. Petersen and G. I. Shulman, “Mechanisms of insulin action and insulin resistance,” Physiol. Rev., 98, No. 4, 2133–2223 (2018).
G. S. Hotamisligil, “Endoplasmic reticulum stress and the infl ammatory basis of metabolic disease,” Cell, 140, 900–917 (2010).
D. E. Lackey and J. M. Olefsky, “Regulation of metabolism by the innate immune system,” Nat. Rev. Endocrinol., 12, 15–28 (2016).
J. M. Olefsky and C. K. Glass, “Macrophages, inflammation, and insulin resistance,” Annu. Rev. Physiol., 72, 219–246 (2010).
K. F. Petersen, S. Dufour, D. Befroy, et al., “Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes,” Diabetes, 54, 603–608 (2005).
A. W. van den Beld, J. M. Kaufman, M. C. Zillikens, et al., “The physiology of endocrine systems with ageing,” Lancet Diabetes Endocrinol., 6, No. 8, 647–658 (2018).
T. Yoneshiro, S. Aita, M. Matsushita, et al., “Recruited brown adipose tissue as an antiobesity agent in humans,” J. Clin. Invest., 123, 3404–3408 (2013).
L. M. Berstein, “Cancer and heterogeneity of obesity: a potential contribution of brown fat,” Future Oncol., 8, No. 12, 1537–1548 (2012).
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Semin. Nephrol., 33, No. 1, 2–13 (2013).
M. G. Saklayen, “The global epidemic of the metabolic syndrome,” Curr. Hypertens. Rep., 20, No. 2, 12 (2018).
A. O. Shpakov, Adipokines and Their Role in the Regulation of Reproductive Functions, Politech-Press, St. Petersburg (2018).
M. Y. Wang, L. Chen, G. O. Clark, et al., “Leptin therapy in insulin-deficient type I diabetes,” Proc. Natl. Acad. Sci. USA, 107, 4813– 4819 (2010).
K. G. Alberti, R. H. Eckel, S. M. Grundy, et al., International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity, “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, 120, 1640–1645 (2009).
H. G. Burger, G. E. Hale, L. Dennerstein, and D. M. Robertson, “Cycle and hormone changes during perimenopause: the key role of ovarian function,” Menopause, 15, No. 4, Pt. 1, 603–612 (2008).
E. A. Lenton, L. Sexton, S. Lee, and I. D. Cooke, “Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life,” Maturitas, 10, No. 1, 35–43 (1988).
A. Stefanska, P. Cembrowska, J. Kubacka, et al., “Gonadotropins and their association with the risk of prediabetes and type 2 diabetes in middle-aged postmenopausal women,” Dis. Markers, 2019: 2384069 (2019).
N. E. Reame, R. P. Kelche, I. Z. Beitins, et al., “Age effects of follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women,” J. Clin. Endocrinol. Metab., 81, No. 4, 1512–1518 (1996).
H. Vanden Brink, D. M. Robertson, H. Lim, et al., “Associations between antral ovarian follicle dynamics and hormone production throughout the menstrual cycle as women age,” J. Clin. Endocrinol. Metab., 100, No. 12, 4553–4562 (2015).
J. C. Prior, “Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation,” Endocrine, 26, No. 3, 297–300 (2005).
K. C. Dafopoulos, “FSH and LH responses to GnRH after ovariectomy in postmenopausal women,” Clin. Endocrinol., 60, No. 1, 120– 124 (2004).
C. Gérard and K. A. Brown, “Obesity and breast cancer – Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue,” Mol. Cell. Endocrinol., 466, 15–30 (2018).
J. D. Veldhuis, “Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women,” Ageing Res. Rev., 7, No. 3, 189–208 (2008).
L. J. Gooren, “Endocrine aspects of ageing in the male,” Mol. Cell. Endocrinol., 145, No. 1–2, 153–159 (1998).
W. B. Neaves, L. Johnson, J. C. Porter, et al., “Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men,” J. Clin. Endocrinol. Metab., 59, No. 4, 756–763 (1984).
W. J. Bremner, M. V. Vitiello, and P. N. Prinz, “Loss of circadian rhythmicity in blood testosterone levels with aging in normal men,” J. Clin. Endocrinol. Metab., 56, No. 6, 1278–1281 (1983).
R. Luboshitzky, Z. Shen-Orr, and P. Herer, “Middle-aged men secrete less testosterone at night than young healthy men,” J. Clin. Endocrinol. Metab., 88, No. 7, 3160–31666 (2003).
S. J. Winters and P. Troen, “Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion,” J. Clin. Endocrinol. Metab., 55, No. 3, 560–565 (1982).
C. Siemes, L. E. Visser, F. H. de Jong, et al., “Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer- The Rotterdam Study,” Steroids, 75, No. 12, 1024–1032 (2010).
M. Barnard, E. A. Mostaghel, R. J. Auchus, and K. H. Storbeck, “The role of adrenal derived androgens in castration resistant prostate cancer,” J. Steroid Biochem. Mol. Biol., 197, 105506 (2019).
H. Eyre, R. Kahn, and R. M. Robertson, ACS/ADA/AHA Collaborative Writing Committee, “Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association and the American Heart Association,” CA Cancer J. Clin., 54, No. 4, 190–207 (2004).
L. M. Berstein, “Dissimilar associations of same metabolic parameters with main chronic noncommunicable diseases (cancer vs some other NCDs),” Future Oncol., 15, No. 35, 4003–4007 (2019).
E. B. Aleksandrova, “Chronic heart failure in patients with arterial hypertension and ischemic heart disease: age and gender characteristics,” Kardiologiya, 53, No. 7, 40–44 (2013).
Y. Ruan, Y. Guo, Y. Zheng, et al., “Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle- income countries: results from SAGE Wave 1,” BMC Public Health, 18, No. 1, 778 (2018).
A. D. Kaprin, V. V. Starinskii, and G. V. Petrova (eds.), Malignant Tumors in Russia in 2018 (Morbidity and Mortality), P. A. Herzen Institute of Oncology, A Branch of the National Medical Radiology Research Center, Russian Ministry of Health, Moscow (2019).
R. Siegel, C. DeSantis, K. Virgo, et al., “Cancer treatment and survivorship statistics,” CA Cancer J. Clin., 62, 220–241 (2012).
M. F. Barginear, H. Muss, G. Kimmick, et al., “Breast cancer and aging: results of the U13 conference breast cancer panel,” Breast Cancer Res. Treat., 146, No. 1, 1–6 (2014).
B. D. Smith, G. L. Smith, A. Hurria, et al., “Future of cancer incidence in the United States: burdens upon an aging, changing nation,” J. Clin. Oncol., 27, 2758–2765 (2009).
M. M. Braun, E. A. Overbeek-Wager, and R. J. Grumbo, “Diagnosis and management of endometrial cancer,” Am. Fam. Physician, 93, No. 6, 468–474 (2016).
S. Ya. Maksimov, A. V. Khadzhimba, E. A. Vyshinskaya, et al., “Cancer of the reproductive organs in youth,” Praktich. Onkol., 18, No. 2, 185–196 (2017).
Ya. V. Bokhman, Handbook of Gynecological Oncology, Meditsina, Leningrad (1989).
V. W. Setiawan, H. P. Yang, M. C. Pike, et al., “Type I and II endometrial cancers: have they different risk factors?” J. Clin. Oncol., 31, No. 20, 2607–2618 (2013).
M. A. Onstad, R. E. Schmandt, and K. H. Lu, “Addressing the role of obesity in endometrial cancer risk, prevention, and treatment,” J. Clin. Oncol., 34, No. 35, 4225–4230 (2016).
A. Talhouk, M. K. McConechy, S. Leung, et al., “Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer,” Cancer, 123, No. 5, 802–813 (2017).
L. M. Berstein, A. G. Iyevleva, A. O. Ivantsov, et al., “Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type?” Future Oncol., 15, No. 12, 1335– 1346 (2019).
K. A. Herget, D. P. Patel, H. A. Hanson, et al., “Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score,” Cancer Med., 5, No. 1, 136–114 (2016).
V. I. Chissov and I. G. Rusakov, “Incidence of prostate cancer in the Russian Federation,” Eksper. Klin. Urol., No. 2–3, 6–7 (2011).
R. Dankner, P. Boffetta, L. Keinan-Boker, et al., “Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men,” Diabetologia, 59, No. 8, 1683–1691 (2016).
K. Esposito, P. Chiodini, A. Colao, et al., “Metabolic syndrome and risk of cancer a systematic review and meta-analysis,” Diabetes Care, 35, No. 11, 2402–2411 (2012).
A. E. Harvey, L. M. Lashinger, and S. D. Hursting, “The growing challenge of obesity and cancer: an infl ammatory issue,” Ann. N. Y. Acad. Sci., 1229, 45–52 (2011).
D. Hong, Y. S. Kim, E. S. Son, et al., “Total testosterone and sex hormone-binding globulin are associated with metabolic syndrome independent of age and body mass index in Korean men,” Maturitas, 74, No. 2, 148–153 (2013).
P. Singh, J. M. Alex, and F. Bast, “Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer,” Med. Oncol., 31, No. 1, 805 (2014).
H. Nandeesha, “Insulin: a novel agent in the pathogenesis of prostate cancer,” Int. Urol. Nephrol, 41, No. 2, 267–272 (2009).
L. M. Berstein, “Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad,” Adv. Exp. Med. Biol., 630, 35–51 (2008).
A. Kasperski and R. Kasperska, “Bioenergetics of life, disease and death phenomena,” Theory Biosci., 137, No. 2, 155–168 (2018).
N. Abolhassani, J. Leon, Z. Sheng, et al., “Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain,” Mech. Aging Dev., 161, 95–104 (2017).
V. N. Anisimov, “Metformin for aging and cancer prevention,” Aging (Albany NY), 2, No. 11, 760–777 (2010).
L. M. Berstein, “Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer,” Cancer Lett., 224, No. 2, 203–212 (2005).
P. Zhu, X. F. Pan, L. Sheng, et al., “Cigarette smoking, diabetes, and diabetes complications: call for urgent action,” Curr. Diab. Rep., 17, No. 9, 78 (2017).
D. Zhu, H. F. Chung, N. Pandeya, et al., “Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies,” PLoS Med., 15, No. 11, e1002704 (2018).
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 106, No. 6, pp. 667–682, Yune, 2020.
About this article
Cite this article
Berstein, L.M., Tsyrlina, E.V. The Hypothalamo-Hypophyseal System: Age and Major Noncommunicable Diseases (malignant neoplasms of hormonedependent tissues, cardiovascular, and type 2 diabetes mellitus). Neurosci Behav Physi 51, 270–278 (2021). https://doi.org/10.1007/s11055-021-01066-6
- hypothalamo-hypophyseal system
- main noncommunicable diseases of humans
- approaches to disease prevention